Clinical trials: nAMD
Neovascular Age-related Macular Degeneration
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
- Trial name
- PHTHALO-205 (NCT04331730)
- Testing
- AKST4290, Aflibercept
- Where
- 21 sites in United States, Germany and 2 more
- Volunteers
- 107 people
- Sponsor
- Alkahest, Inc.
Macular Degeneration
Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).
- Trial name
- XPLORE (NCT03805100)
- Testing
- Ranibizumab
- Where
- 102 sites in United States, Bulgaria and 13 more
- Volunteers
- 582 people
- Sponsor
- Xbrane Biopharma AB
Neovascular Age-related Macular Degeneration
Vessel Density in nAMD After Longterm Anti-VEGF Treatment Compared to Recently Started Anti-VEGF Treatment
Neovascular age-related macular degeneration (nAMD) is characterized by the abnormal growth of blood vessels from the choroid into the subretinal space which leads to sub- and intraretinal fluid accumulation, hemorrhages and…
- Trial name
- NCT03833830
- Testing
- Optical Coherence Tomography angiography (OCTA)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Dr. med. Katja Hatz
Age-Related Macular Degeneration
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
KH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain…
- Trial name
- NCT05672121
- Testing
- KH631
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
Neovascular Age-related Macular Degeneration
Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD)
The goal of this study is to evaluate the safety and efficacy of LX102-C01 treatment of nAMD. This study will enroll subjects aged ≥ 50 years old to receive a single unilateral intravitreal (IVT) injection of LX102-C01 to…
- Trial name
- NCT05831007
- Testing
- LX102-C01 Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (nAMD) also referred to as Wet AMD.
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration
- Trial name
- NCT04832724
- Testing
- RGX-314
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- AbbVie
Neovascular Age-related Macular Degeneration (nAMD)
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.
- Trial name
- NCT05282004
- Testing
- SOK583A1
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sandoz
Age Related Macular Degeneration
Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting
Neovascular age-related macular degeneration (nAMD), also called wet AMD, can cause serious vision loss. While anti-VEGF (anti Vascular Endothelial Growth Factor) treatments such as ranibizumab help many patients, about 20 40%…
- Trial name
- M-VIVA (NCT07249216)
- Testing
- Faricimab, Ranibizumab
- Where
- Singapore
- Volunteers
- 117 people
- Sponsor
- Singapore National Eye Centre
Neovascular Age-related Macular Degeneration(nAMD), Wet Macular Degeneration
LEAP Strategy for Neovascular Age-Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is a common eye disease that can cause blindness in older adults. The "wet" form of AMD, called neovascular AMD, happens when abnormal blood vessels grow under the retina and…
- Trial name
- LEAP (NCT07744204)
- Testing
- Laser photocoagulation, Anti-VEGF agents
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital
Retinal Vasculitis
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice.
- Trial name
- NCT06769412
- Testing
- aflibercept 2 mg
- Where
- United States
- Volunteers
- 550,000 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Researchers are looking for a better way to treat participants who have diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD). DME is a diabetes-related eye disorder.
- Trial name
- DEUTERON (NCT06591598)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 51 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration(nAMD)
Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)
Evaluate the benefit of faricimab (4 loading doses + PRN) on best-corrected visual acuity in patients with nAMD. Evaluate the safety and anatomical improvement of faricimab (4 loading doses + PRN) in patients with nAMD.
- Trial name
- NCT07581782
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Neovascular Age-related Macular Degeneration
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
- Trial name
- COAST (NCT04757636)
- Testing
- 2.0 mg OPT-302, 2.0 aflibercept
- Where
- 209 sites in United States, Argentina and 28 more
- Volunteers
- 998 people
- Sponsor
- Opthea Limited
Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD)
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
This is an observational study in which only data are collected from people who have already been prescribed aflibercept 8 mg by their own doctors.
- Conditions
- Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME)
- Trial name
- NCT06075147
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- 18 sites in Australia, Canada and 16 more
- Volunteers
- 2,500 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
Excessive vascular endothelial growth factor (VEGF) plays a key part in promoting neovascularization and edema in neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- NCT03066258
- Testing
- RGX-314
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- REGENXBIO Inc.
Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
- Trial name
- JADE (NCT07484074)
- Testing
- Faricimab, OLN324
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 164 people
- Sponsor
- Ollin Biosciences, Inc.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Supplemental Adjuvants for Intracellular Nutrition and Treatment
Nutritional supplements have an augmentative effect on the outcomes of standard treatment of diabetic macular edema (DME) and Neovascular Age-Related Macular Degeneration (NAMD).
- Trial name
- SAINTS (NCT00893724)
- Testing
- Neutral pills with no medicinal effect, Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals, Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mid-Atlantic Retina Consultations, Inc.
Wet Age-related Macular Degeneration (wAMD)
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg).
- Trial name
- HEIRLOOM (NCT07129239)
- Testing
- Maintenance
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- Clinique de Retine de l'est
Neovascular Age-related Macular Degeneration
Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.
- Trial name
- NCT05131646
- Testing
- CLS-AX
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Clearside Biomedical, Inc.
Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO
This is an observational study in which data already collected from people with the eye disorders below are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- AIRSPEED (NCT06495203)
- Testing
- anti-VEGF treatment
- Where
- Canada
- Volunteers
- 1,350 people
- Sponsor
- Bayer